Literature DB >> 15273112

Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods.

T J J Inglis1, F Rodrigues, P Rigby, R Norton, B J Currie.   

Abstract

The effect of the two antibiotics ceftazidime and meropenem on a collection of 46 Burkholderia pseudomallei isolates representing clinical and environmental sources across northern Australia was investigated by using a series of in vitro test methods. The susceptibility testing methods used included Kirby-Bauer disk diffusion, Etest MIC, broth microdilution MIC, and a modification of the microdilution method in which Acanthamoeba cells were added to simulate the effect of a professional phagocytic cell on test outcome. In a semiquantitative validation coculture series, the majority of bacteria were intracellular up to a multiplicity of infection of 10 bacteria to one ameba. The optical density and bacterial count (log10 CFU/ml) correlated across the range tested (r2 = 0.77; P < 0.0001). Susceptibility test results were compared against clinical outcomes. The MICs of ceftazidime were consistently higher than those of meropenem by all three methods. The MICs of both agents were significantly higher when Acanthamoeba trophozoites were added to the broth microdilution method. Conventional and intracellular MIC results were consistent for clinical isolates from the Western Australian outbreak cluster despite the wide variety of clinical outcomes. Further development of the intracellular MIC method is expected to help assess the efficacy of antimicrobial agents on this bacterial species in an intracellular setting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273112      PMCID: PMC478517          DOI: 10.1128/AAC.48.8.2999-3005.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei.

Authors:  M D Smith; V Wuthiekanun; A L Walsh; N J White
Journal:  J Antimicrob Chemother       Date:  1996-03       Impact factor: 5.790

2.  Interaction between Burkholderia pseudomallei and Acanthamoeba species results in coiling phagocytosis, endamebic bacterial survival, and escape.

Authors:  T J Inglis; P Rigby; T A Robertson; N S Dutton; M Henderson; B J Chang
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  The epidemiology of melioidosis in Australia and Papua New Guinea.

Authors:  B J Currie; D A Fisher; D M Howard; J N Burrow; S Selvanayagam; P L Snelling; N M Anstey; M J Mayo
Journal:  Acta Trop       Date:  2000-02-05       Impact factor: 3.112

4.  Case report: recovery from persistent septicemic melioidosis.

Authors:  T J Inglis; C L Golledge; A Clair; J Harvey
Journal:  Am J Trop Med Hyg       Date:  2001-07       Impact factor: 2.345

5.  Comparison of imipenem and ceftazidime as therapy for severe melioidosis.

Authors:  A J Simpson; Y Suputtamongkol; M D Smith; B J Angus; A Rajanuwong; V Wuthiekanun; P A Howe; A L Walsh; W Chaowagul; N J White
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

6.  Intracellular survival of Burkholderia pseudomallei.

Authors:  A L Jones; T J Beveridge; D E Woods
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

7.  Comparison of rapid, automated ribotyping and DNA macrorestriction analysis of Burkholderia pseudomallei.

Authors:  Timothy J J Inglis; Lyn O'Reilly; Niki Foster; Adele Clair; Judy Sampson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

8.  Relapse in melioidosis: incidence and risk factors.

Authors:  W Chaowagul; Y Suputtamongkol; D A Dance; A Rajchanuvong; J Pattara-arechachai; N J White
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

9.  Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis.

Authors:  A W Jenney; G Lum; D A Fisher; B J Currie
Journal:  Int J Antimicrob Agents       Date:  2001-02       Impact factor: 5.283

10.  Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents.

Authors:  M B Huang; C N Baker; S Banerjee; F C Tenover
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

View more
  14 in total

1.  In vitro activity of doripenem against Burkholderia pseudomallei.

Authors:  Visanu Thamlikitkul; Suwanna Trakulsomboon
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

2.  Endophthalmitis: potential benefits of repeated intravitreal injections of antibiotics.

Authors:  M Hui; W H Lam; W H Ho; C Y Chan
Journal:  J Clin Microbiol       Date:  2008-04       Impact factor: 5.948

Review 3.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

4.  Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Authors:  Vanaporn Wuthiekanun; Premjit Amornchai; Natnaree Saiprom; Narisara Chantratita; Wirongrong Chierakul; Gavin C K W Koh; Wipada Chaowagul; Nicholas P J Day; Direk Limmathurotsakul; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

5.  In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.

Authors:  Visanu Thamlikitkul; Suwanna Trakulsomboon
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Rapid Antimicrobial Susceptibility Testing of Bacillus anthracis, Yersinia pestis, and Burkholderia pseudomallei by Use of Laser Light Scattering Technology.

Authors:  Julia V Bugrysheva; Christine Lascols; David Sue; Linda M Weigel
Journal:  J Clin Microbiol       Date:  2016-03-16       Impact factor: 5.948

7.  Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis.

Authors:  Julia V Bugrysheva; David Sue; Jay E Gee; Mindy G Elrod; Alex R Hoffmaster; Linnell B Randall; Sunisa Chirakul; Apichai Tuanyok; Herbert P Schweizer; Linda M Weigel
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Safer In Vitro Drug Screening Models for Melioidosis Therapy Development.

Authors:  Anna S Amiss; Jessica R Webb; Mark Mayo; Bart J Currie; David J Craik; Sónia Troeira Henriques; Nicole Lawrence
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

9.  Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin.

Authors:  Barbara M Judy; Gregory C Whitlock; Alfredo G Torres; D Mark Estes
Journal:  BMC Microbiol       Date:  2009-05-09       Impact factor: 3.605

Review 10.  The Treatment of Melioidosis.

Authors:  Timothy J J Inglis
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.